These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 17024814)

  • 1. [Modulating effect of antileukemia drugs on the cellular susceptibility in chronic myeloid leukemia to cytotoxic lymphocytes].
    Cherepovich VS; Shakhlevich EV; Antonenko EV; Lotkova ES; Grinëv VV
    Vopr Onkol; 2006; 52(4):417-20. PubMed ID: 17024814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined use of busulfan and hydroxyurea in the treatment of chronic myeloid leukemia.
    Jim RT
    Hawaii Med J; 1990 Apr; 49(4):133-4. PubMed ID: 2341244
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
    Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
    Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
    Miething C; Grundler R; Mugler C; Brero S; Hoepfl J; Geigl J; Speicher MR; Ottmann O; Peschel C; Duyster J
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4594-9. PubMed ID: 17360569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
    Komarova NL; Wodarz D
    Cancer Res; 2009 Jun; 69(11):4904-10. PubMed ID: 19458080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
    Carella AM
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
    Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.
    Nanda S; Moore H; Lenhart S
    Math Biosci; 2007 Nov; 210(1):143-56. PubMed ID: 17599363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells.
    Zhou HJ; Wang WQ; Wu GD; Lee J; Li A
    Vascul Pharmacol; 2007; 47(2-3):131-8. PubMed ID: 17581794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
    Lundán T; Juvonen V; Mueller MC; Mustjoki S; Lakkala T; Kairisto V; Hochhaus A; Knuutila S; Porkka K
    Haematologica; 2008 Feb; 93(2):178-85. PubMed ID: 18223279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells.
    Mao X; Yu CR; Li WH; Li WX
    Cell Res; 2008 Aug; 18(8):879-88. PubMed ID: 18663379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.